Determine the necessary mass, volume, or concentration for preparing a solution.
This is a demo store. No orders will be fulfilled.
| SKU | Size | Availability |
Price | Qty |
|---|---|---|---|---|
|
Q412686-5mg
|
5mg |
3
|
$155.90
|
|
|
Q412686-10mg
|
10mg |
3
|
$273.90
|
|
|
Q412686-50mg
|
50mg |
3
|
$547.90
|
|
HDAC8 Selective Inhibitors
| Synonyms | N-hydroxy-2-(4-(((1-methyl-1H-indol-3-yl)methylamino)methyl)piperidin-1-yl)pyrimidine-5-carboxamide dihydrochloride |
|---|---|
| Specifications & Purity | ≥98% |
| Biochemical and Physiological Mechanisms | Quisinostat (JNJ-26481585) 2HCl is a novel second-generation HDAC inhibitor with highest potency for HDAC1 with IC50 of 0.11 nM in a cell-free assay, modest potent to HDACs 2, 4, 10, and 11; greater than 30-fold selectivity against HDACs 3, 5, 8, and 9 an |
| Storage Temp | Store at -20°C |
| Shipped In |
Ice chest + Ice pads This product requires cold chain shipping. Ground and other economy services are not available. |
| Product Description |
Information Quisinostat (JNJ-26481585) 2HCl is a novel second-generationHDACinhibitor with highest potency for HDAC1 withIC50of 0.11 nM in a cell-free assay, modest potent to HDACs 2, 4, 10, and 11; greater than 30-fold selectivity against HDACs 3, 5, 8, and 9 and lowest potency to HDACs 6 and 7. Phase 2. Targets HDAC1 (Cell-free assay); HDAC2 (Cell-free assay); HDAC11 (Cell-free assay); HDAC10 (Cell-free assay); HDAC4 (Cell-free assay) 97,0.11 nM; 0.33 nM; 0.37 nM; 0.46 nM; 0.64 nM In vitro JNJ-26481585 exhibits broad spectrum antiproliferative activity in solid and hematologic cancer cell lines, such as all lung, breast, colon, prostate, brain, and ovarian tumor cell lines, with IC50 ranging from 3.1-246 nM, which is more potent than vorinostat, R306465, panobinostat, CRA-24781, or mocetinostat in various human cancer cell lines tested. A recent study shows that JNJ-26481585 promotes myeloma cell death at low nanomolar concentrations by resulting in Mcl-1 depletion and Hsp72 induction. In vivo In an HDAC1-responsive A2780 ovarian tumor screening model, JNJ-26481585 dosing at its maximal tolerated dose (10 mg/kg i.p. and 40 mg/kg p.o.) for 3 days leads to an HDAC1-regulated fluorescence , which predicts tumor growth inhibition. Furthermore, JNJ-26481585 also shows more potent inhibitory effects on the growth of C170HM2 colorectal liver metastases than 5-fluorouracil/Leucovorin. Cell Research(from reference) Cell lines:NCL-H2106, Colo699 and LNCAP cells Concentrations:0-300 nM Incubation Time:24 hours |
| ALogP | 2.749 |
|---|---|
| HBD Count | 2 |
| Rotatable Bond | 6 |
| Pubchem Sid | 504772960 |
|---|---|
| Pubchem Sid Url | https://pubchem.ncbi.nlm.nih.gov/substance/504772960 |
| IUPAC Name | N-hydroxy-2-[4-[[(1-methylindol-3-yl)methylamino]methyl]piperidin-1-yl]pyrimidine-5-carboxamide;dihydrochloride |
| INCHI | InChI=1S/C21H26N6O2.2ClH/c1-26-14-17(18-4-2-3-5-19(18)26)11-22-10-15-6-8-27(9-7-15)21-23-12-16(13-24-21)20(28)25-29;;/h2-5,12-15,22,29H,6-11H2,1H3,(H,25,28);2*1H |
| InChIKey | NRUIZESXVMJDKR-UHFFFAOYSA-N |
| Smiles | CN1C=C(C2=CC=CC=C21)CNCC3CCN(CC3)C4=NC=C(C=N4)C(=O)NO.Cl.Cl |
| PubChem CID | 122129987 |
| Molecular Weight | 467.39 |
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
| Certificate of Analysis | Apr 07, 2024 | Q412686 | |
| Certificate of Analysis | Apr 07, 2024 | Q412686 | |
| Certificate of Analysis | Apr 07, 2024 | Q412686 |
| Solubility | Solubility (25°C) In vitro DMSO: 79 mg/mL (169.02 mM); Water: Insoluble; Ethanol: Insoluble; |
|---|---|
| DMSO(mg / mL) Max Solubility | 79 |
| DMSO(mM) Max Solubility | 169.0237275 |
| Water(mg / mL) Max Solubility | <1 |
| Molecular Weight | 467.400 g/mol |
| XLogP3 | |
| Hydrogen Bond Donor Count | 5 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 6 |
| Exact Mass | 466.165 Da |
| Monoisotopic Mass | 466.165 Da |
| Topological Polar Surface Area | 95.300 Ų |
| Heavy Atom Count | 31 |
| Formal Charge | 0 |
| Complexity | 533.000 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| The total count of all stereochemical bonds | 0 |
| Covalently-Bonded Unit Count | 3 |